Skip to main content
Caplight Logo









Synthace

Synthace

Private
London, EnglandEnterprise Softwarehttps://www.synthace.com

Last Round

Series C

Nov 16, 2021

Est. Valuation

$71.3M

Total Funding Raised

$76.37M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Synthace is a biotechnology company that offers a laboratory automation platform aimed at transforming biological experimentation by streamlining data management and facilitating the planning and execution of complex experiments.

Sector

Enterprise Software

Verticals

Drug Discovery, Biotechnology, Workflow Automation, Low-Code/No-Code, Vertical SaaS

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting

AI Layer

Application

Keywords

Life Sciences R&D Cloudlab automation softwareno-code lab automationDesign of ExperimentsDOEdrug discoveryscientific workflow automationanalysis-ready datalab orchestrationcloud labLab of the Futureexperiment simulationbioprocess developmentdigital biologyassay developmentCDMOAI scientist

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Synthace Comparables

Compare Synthace with similar companies based on industry and business-model similarity.

Synthace comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Labforward
82%
TetraScience
80%
Artificial, Inc.
80%

Synthace Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CNov 16, 2021
Series BDec 12, 2018
Series ASep 19, 2017
SeedFeb 11, 2015
SeedSep 23, 2014
Grant
Mar 7, 2013

Key People

Founding team and executive leadership

Markus Gershater

Chief Scientific Officer and Cofounder

Founding Team

Synthace Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors increased 32% MoM.

  • Apr 1, 2026

    Added Charles River Laboratories International as a customer.

Synthace Filings

Explore SEC and related filing metadata, where available.

Synthace filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Synthace's valuation, stock price, and market status.

Is Synthace a public or private company?

Synthace is a private company.

What is the current stock price of Synthace?

Synthace is a private company with no public stock price. No recent secondary market data is available.

How much is Synthace worth (valuation)?

Synthace's valuation is estimated at $71.3M based on funding round data.

Can I buy Synthace stock?

Synthace shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Synthace's last funding round?

Synthace's most recent funding round was Series C on December 12, 2018.

Who are the main investors in Synthace?

Key investors in Synthace include Horizons Ventures, Sofinnova Partners, 11.2 Capital.

Will Synthace IPO soon?

No public IPO plans have been announced for Synthace.

How can I track Synthace secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Synthace's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLondon, England
Employee Range30
Year Founded2011
Last FundingNov 16, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?